IQM
1.7.2021 13:02:09 CEST | Business Wire | Press release
IQM Quantum Computers (IQM) expands its operations to Spain, creating a subsidiary in Bilbao. This operation has been supported by Basque local administration via Provincial Council of Bizkaia and Bilbao City Hall.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005046/en/
With its Spain operations, IQM aims to tap into another hotspot for quantum computing in addition to its Finland and Germany offices. IQM Spain will collaborate closely with the local research community, quantum experts from academia and the industry to build a vibrant Spanish and European quantum ecosystem. IQM with its international partner network will also connect the Spanish quantum ecosystem to the global quantum network.
“QUTIS Center in University of the Basque Country Bilbao has outstanding experience and experts in quantum computation and simulation, quantum control, quantum sensing and other areas. Today’s announcement signals our commitment to accelerate the success of our application-specific quantum computers, and aggressively develop quantum finance offerings for our customers worldwide,” said Jan Goetz, CEO at IQM. “Local Public Administration, via Beaz and Bilbao Ekintza, have been extremely supportive and are committed to attracting best talent and growth companies. We look forward to working with their team to grow our Co-Design offering from Spain and deliver it globally.”
The technical goal for this Spanish subsidiary is to create a quantum finance Co-Design hub that tightens the interaction between hardware and software to solve problems in finance. In particular, IQM Spain will develop an application-specific approach where quantum software integrates closely with a suitably designed quantum hardware with novel quantum architectures. Combined with IQM's hardware experts and go-to market teams in Finland and Germany, IQM will be able to deliver this offering to global customers. This approach accelerates the development of useful quantum solutions for specialized financial applications and will establish Spain and Europe as the leaders for quantum finance.
Last year, IQM had also entered into a research agreement with the University of the Basque Country (UPV/EHU) in Bilbao, a collaboration led by Dr. Jorge Casanova (Ramón y Cajal and Ikerbasque researcher at UPV/EHU) and includes Dr. Mikel Sanz (Ikerbasque Researcher at UPV/EHU) and Prof. Xi Chen (Professor at Shanghai University and Ramon y Cajal researcher at UPV/EHU).
Ms. Olatz Goitia, General Manager of Beaz, said, “We work to turn the territory into an innovation hub of international reference, and to this end, the retention and attraction of talent and entrepreneurship and companies like IQM is key.”
Mr. Javier Garcinuño Zabala, General Manager of Bilbao Ekintza, said, “We’re pleased to see European growth companies like IQM start their Spanish operations in Bilbao. Our BIG Bilbao entrepreneurship centre will support their local operations and Bilbao Ekintza will also collaborate with IQM on joint projects in Bilbao’s strategic economic sectors.”
About Beaz:
Beaz is a public company of the Provincial Council of Bizkaia whose objective is to support companies and entrepreneurs in their efforts to create new projects, innovate and internationalize. A goal that is in line with that of the Regional Department of Economic Promotion, to which Beaz reports directly: to contribute to the growth of economic activity and the creation of qualified employment.
About Bilbao Ekintza:
Bilbao Ekintza is a public company of Bilbao City Hall that develops the municipal powers in the field of economic development, promotion of Bilbao and its events as a tourist destination and business promotion, both from the point of view of the attraction, creation and growth of companies and the improvement of opportunities for access to employment.
https://www.bilbaoekintza.eus/en
About IQM Quantum Computers:
IQM is the European leader in superconducting quantum computers, headquartered in Espoo, Finland. Since its inception in 2018, IQM has grown to 110+ employees and established a subsidiary in Munich, Germany, to lead the Co-Design approach.
IQM delivers on-premises quantum computers for research laboratories and supercomputing centers and provides complete access to its hardware. For industrial customers, IQM delivers quantum advantage through a unique application-specific Co-Design approach.
IQM is building Finland’s first commercial quantum computer with VTT, and an IQM-led consortium was awarded € 12.4 Million in February 2021 to commercialize application-specific quantum processors by the German Ministry of Education and Research.
For more information, visit www.meetiqm.com .
Registered office:
IQM Finland Oy
Keilaranta 19
02150 Espoo
Finland
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005046/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 11:15:00 CEST | Press release
The first SaaS SuperApp for startups and VCs capitalizes on a $25M round a from Nimbus Capital and a +15% stock surge, unveiling a v3/v4 roadmap that bridges public equity with digital asset liquidity. HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026061293689
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom